Stock Screener App

무료 -

설치하다

21.04

5.15% 1.03

Newamsterdam Pharma Company Nv (NAMS)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스

After exercising options, Futurum sold 50,246 NewAmsterdam Pharma (NAMS) shares at an average $25.03. - stocktitan.net

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK

Seven new hires receive stock options to buy NewAmsterdam shares at $24.16 each. - stocktitan.net

Five Frazier funds detail their NewAmsterdam (NASDAQ: NAMS) positions - Stock Titan

NewAmsterdam Pharma (NasdaqGM:NAMS) Stock Forecast & Analyst Predictions - Simply Wall Street

NewAmsterdam Pharma (NAMS) CEO adds to stake with fresh share purchase - Stock Titan

Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily

NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test - Investing.com

NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test By Investing.com - Investing.com UK

Newamsterdam Pharma stock hits 52-week low at 23.02 USD By Investing.com - Investing.com Nigeria

NewAmsterdam Pharma at Wells Fargo conference: obicetrapib push By Investing.com - Investing.com UK

NewAmsterdam Pharma (NAMS) director sells shares to cover tax bill - Stock Titan

Newamsterdam Pharma stock hits 52-week low at 23.02 USD - investing.com

Newamsterdam Pharma stock hits 52-week low at 23.02 USD - Investing.com India

Newamsterdam Pharma stock hits 52-week low at 23.02 USD By Investing.com - Investing.com UK

NewAmsterdam Pharma: Potential Coupled With Uncertainty (NASDAQ:NAMS) - Seeking Alpha

Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com Nigeria

Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com South Africa

Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure - Investing.com

Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com India

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga

Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com UK

Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure - Investing.com

Price to earnings forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView

Why (NAMSW) Price Action Is Critical for Tactical Trading - Stock Traders Daily

NewAmsterdam Pharma Company N.V. - Reuters

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

NewAmsterdam Pharma VP Robert Gunning Granted 3,200 RSUs and 14,000 Stock Options - kalkinemedia.com

NewAmsterdam Pharma (NAMS) awards 14,000 options and 3,200 RSUs to controller - Stock Titan

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

NAMS Q2 2026 Earnings: Quarterly Net Loss Widens Slightly on R&D InvestmentPre-Earnings Setup - vinanet.vn

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

New hires receive options to buy NewAmsterdam shares at $24.92. Some awards vest over four years. - Stock Titan

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - The Manila Times

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - GlobeNewswire

Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Barchart.com

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance

NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW) Stock Price, News & Analysis - kalkine.ca

NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW) Stock Price, News & Analysis - Kalkine

NewAmsterdam Pharma (NASDAQ: NAMS) affiliate plans Nasdaq share sale over 90 days - Stock Titan

NewAmsterdam Pharma (NASDAQ: NAMS) affiliate readies Nasdaq share sale - Stock Titan

NewAmsterdam (NAMSW) Shares: Moves 3.19% Higher to $16.51; Level Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingFactor Momentum - vinanet.vn

NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayMargin Expansion Trends - dars.gov.et

NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayEarnings Miss Alert - dars.gov.et

NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayDownward Estimate Revision - dars.gov.et

NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayEarnings Acceleration Picks - vinanet.vn

NewAmsterdam (NAMSW) Shares: Shows Minimal Net Change at $16.00 in Latest Trading; Trading Range: Support at $15.20 and Resistance at $16.80 Frame the Range in the Latest SessionSingle Stock ETF - vinanet.vn

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

BEAM

$24.30

2.75%

ADMA

$10.72

3.68%

PGEN

$7.345

0.14%

MBX

$49.63

1.66%

ZLAB

$23.59

4.84%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개